These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 11280801)
1. Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model. Demidem A; Morvan D; Papon J; De Latour M; Madelmont JC Cancer Res; 2001 Mar; 61(5):2294-300. PubMed ID: 11280801 [TBL] [Abstract][Full Text] [Related]
2. Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples. Morvan D; Demidem A; Papon J; De Latour M; Madelmont JC Cancer Res; 2002 Mar; 62(6):1890-7. PubMed ID: 11912170 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy-induced bystander effect in response to several chloroethylnitrosoureas: an origin independent of DNA damage? Merle P; Morvan D; Caillaud D; Demidem A Anticancer Res; 2008; 28(1A):21-7. PubMed ID: 18383820 [TBL] [Abstract][Full Text] [Related]
4. Enhancement by O6-benzyl-N-acetylguanosine derivatives of chloroethylnitrosourea antitumor action in chloroethylnitrosourea-resistant human malignant melanocytes. Cussac C; Rapp M; Mounetou E; Madelmont JC; Maurizis JC; Godeneche D; Dupuy JM; Sauzieres J; Baudry JP; Veyre A J Pharmacol Exp Ther; 1994 Dec; 271(3):1353-8. PubMed ID: 7996446 [TBL] [Abstract][Full Text] [Related]
5. Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Morvan D; Demidem A Cancer Res; 2007 Mar; 67(5):2150-9. PubMed ID: 17332345 [TBL] [Abstract][Full Text] [Related]
6. CENU treatment induced bystander effects which are effective on parental and non-parental tumors and have a phospholipid metabolism proton NMR spectroscopy signature. Merle P; Morvan D; Madelmont JC; Caillaud D; Demidem A Int J Oncol; 2006 Sep; 29(3):637-42. PubMed ID: 16865279 [TBL] [Abstract][Full Text] [Related]
7. A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models. Rapp M; Maurizis JC; Papon J; Labarre P; Wu TD; Croisy A; Guerquin-Kern JL; Madelmont JC; Mounetou E J Pharmacol Exp Ther; 2008 Jul; 326(1):171-7. PubMed ID: 18411412 [TBL] [Abstract][Full Text] [Related]
8. Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. Da Costa ML; Redmond HP; Bouchier-Hayes DJ J Surg Res; 2001 Dec; 101(2):111-9. PubMed ID: 11735264 [TBL] [Abstract][Full Text] [Related]
9. PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. Guénin S; Schwartz L; Morvan D; Steyaert JM; Poignet A; Madelmont JC; Demidem A Int J Oncol; 2008 Jan; 32(1):49-57. PubMed ID: 18097542 [TBL] [Abstract][Full Text] [Related]
10. Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)- hydrazines. Shyam K; Penketh PG; Loomis RH; Rose WC; Sartorelli AC J Med Chem; 1996 Feb; 39(3):796-801. PubMed ID: 8576923 [TBL] [Abstract][Full Text] [Related]
11. Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. Gil-Ad I; Shtaif B; Levkovitz Y; Nordenberg J; Taler M; Korov I; Weizman A Oncol Rep; 2006 Jan; 15(1):107-12. PubMed ID: 16328041 [TBL] [Abstract][Full Text] [Related]
12. G2 accumulation and melanin overproduction in malignant melanocytes treated with a new nitrosourea. Buchdahl C; Papon J; Communal Y; Bourges M; Madelmont JC Melanoma Res; 1998 Dec; 8(6):517-27. PubMed ID: 9918414 [TBL] [Abstract][Full Text] [Related]
13. Combined methionine deprivation and chloroethylnitrosourea have time-dependent therapeutic synergy on melanoma tumors that NMR spectroscopy-based metabolomics explains by methionine and phospholipid metabolism reprogramming. Guénin S; Morvan D; Thivat E; Stepien G; Demidem A Nutr Cancer; 2009; 61(4):518-29. PubMed ID: 19838924 [TBL] [Abstract][Full Text] [Related]
14. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination]. Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746 [TBL] [Abstract][Full Text] [Related]
15. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Duguay D; Mercier F; Stagg J; Martineau D; Bramson J; Servant M; Lin R; Galipeau J; Hiscott J Cancer Res; 2002 Sep; 62(18):5148-52. PubMed ID: 12234977 [TBL] [Abstract][Full Text] [Related]
16. Antiproliferative action of isatine-beta-thiocarbohydrazone and N-ethylisatine-beta-thiocarbohydrazone on human PBMC and on two neoplastic cell lines. Juranić Z; Anastasova F; Juranić I; Stanojković T; Radulović S; Vuletić N J Exp Clin Cancer Res; 1999 Sep; 18(3):317-24. PubMed ID: 10606176 [TBL] [Abstract][Full Text] [Related]
17. Role of transglutaminase 2 in quercetin-induced differentiation of B16-F10 murine melanoma cells. Forni C; Braglia R; Lentini A; Nuccetelli M; Provenzano B; Tabolacci C; Beninati S Amino Acids; 2009 Apr; 36(4):731-8. PubMed ID: 18688565 [TBL] [Abstract][Full Text] [Related]
18. Synthetic phosphoethanolamine a precursor of membrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10 and in vitro induce apoptosis and arrest in G2/M phase. Ferreira AK; Meneguelo R; Marques FL; Radin A; Filho OM; Neto SC; Chierice GO; Maria DA Biomed Pharmacother; 2012 Oct; 66(7):541-8. PubMed ID: 22902646 [TBL] [Abstract][Full Text] [Related]